The global FPR2 Agonists and Antagonists market was valued at US$ 126 million in 2025 and is anticipated to reach US$ 356 million by 2032, at a CAGR of 16.4% from 2026 to 2032.

FPR2 Agonists and Antagonists Market

The FPR2 agonist and antagonist industry has a gross profit margin of 50%-70%.

FPR2 agonists: Molecules that bind to N-formyl peptide receptor 2 (FPR2/ALX) and activate the receptor conformation and downstream signal transduction (which can manifest as complete agonism, partial agonism, or "biased agonism"). A common characteristic of the FPR2 system is that the ligand can induce different signal biases and biological effects (e.g., pro-inflammatory or pro-inflammatory resolution/repair), therefore, research and development often further subdivides according to "bias."

FPR2 antagonists are peptides that bind to FPR2 and block receptor activation induced by agonists (typically manifested as inhibition of Ca²⁺ mobilization, chemotaxis, and other readouts). They are used in tool research or potential therapeutic strategies to "inhibit certain pathological responses mediated by FPR2." Some commonly used tool antagonist peptides (e.g., WRW4) are frequently used to validate the specificity of FPR2-related effects.

From a "raw material" perspective, FPR2 agonists/antagonists most commonly fall into two categories in research and development and supply: peptides and small molecules/lipids. Peptides (many tool agonist and antagonist peptides) are typically synthesized using solid-phase peptide synthesis (SPPS): the main raw materials are amino acid monomers, resin carriers, coupling/deprotection reagents, and large amounts of organic solvents, and they are highly dependent on HPLC purification and mass spectrometry analysis for release. Therefore, the cost structure often shows a high proportion of "purification and detection," with longer sequences, more hydrophobic sequences, or a greater likelihood of byproduct formation increasing the unit cost. Upgrading from research-grade to GMP-grade significantly increases costs due to additional documentation, validation, and more stringent testing.

For FPR2 agonist routes involving lipid mediators/lipoxygen-like molecules (or their mimics), the raw materials often come from chiral/unsaturated fragments, protecting groups, and solvents required for multi-step organic synthesis. This makes the cost more easily amplified by factors such as chemical instability, isomer control, low-temperature and light-protected storage and transportation, and complex purification. This is why many R&D efforts shift towards more stable mimics/small molecule agonists with better physicochemical properties to improve manufacturability and cost control.

Overall conclusion: Under the same purity and traceability requirements, short peptides have relatively more predictable costs but are expensive to purify and detect; lipids/complex small molecules are more affected by synthetic difficulty and stability/storage and transportation, resulting in greater fluctuations in unit cost.

The North American market for FPR2 Agonists and Antagonists is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

The Asia-Pacific market for FPR2 Agonists and Antagonists is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

The global market for FPR2 Agonists and Antagonists in Pharmaceutical Company is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 to 2032.

Major global companies of FPR2 Agonists and Antagonists include Bio-Techne, Abcam, Enzo Life Sciences, MedChemExpress, Anaspec, Merck, Discoverx, BioGems, GenScript Company, Alomone Labs, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.

This report delivers a comprehensive overview of the global FPR2 Agonists and Antagonists market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding FPR2 Agonists and Antagonists. The FPR2 Agonists and Antagonists market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global FPR2 Agonists and Antagonists market comprehensively. Regional market sizes by Type, by Application, by Molecular Type, and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist FPR2 Agonists and Antagonists manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of FPR2 Agonists and Antagonists Market Report

Report Metric	Details
Report Name	FPR2 Agonists and Antagonists Market
Accounted market size in 2025	US$ 126 million
Forecasted market size in 2032	US$ 356 million
CAGR	16.4%
Base Year	2025
Forecasted years	2026 - 2032
Segment by Type	Agonists Antagonists
Segment by Molecular Type	Lipid Mediators Peptides Proteins Small Molecule Synthetic Compounds
Segment by Source	Endogenous Exogenous
Segment by Application	Pharmaceutical Company Universities and Research Institutes Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Bio-Techne, Abcam, Enzo Life Sciences, MedChemExpress, Anaspec, Merck, Discoverx, BioGems, GenScript Company, Alomone Labs
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Molecular Type, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for FPR2 Agonists and Antagonists companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.

FAQ for this report

How fast is FPR2 Agonists and Antagonists Market growing?

Ans: The FPR2 Agonists and Antagonists Market witnessing a CAGR of 16.4% during the forecast period 2026-2032.

What is the FPR2 Agonists and Antagonists Market size in 2032?

Ans: The FPR2 Agonists and Antagonists Market size in 2032 will be US$ 356 million.

Who are the main players in the FPR2 Agonists and Antagonists Market report?

Ans: The main players in the FPR2 Agonists and Antagonists Market are Bio-Techne, Abcam, Enzo Life Sciences, MedChemExpress, Anaspec, Merck, Discoverx, BioGems, GenScript Company, Alomone Labs

What are the Application segmentation covered in the FPR2 Agonists and Antagonists Market report?

Ans: The Applications covered in the FPR2 Agonists and Antagonists Market report are Pharmaceutical Company, Universities and Research Institutes, Others

What are the Type segmentation covered in the FPR2 Agonists and Antagonists Market report?

Ans: The Types covered in the FPR2 Agonists and Antagonists Market report are Lipid Mediators, Peptides, Proteins, Small Molecule Synthetic Compounds

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global FPR2 Agonists and Antagonists Market Size Growth Rate by Type: 2021 vs 2025 vs 2032

1.2.2 Agonists

1.2.3 Antagonists

1.3 Market by Molecular Type

1.3.1 Global FPR2 Agonists and Antagonists Market Size Growth Rate by Molecular Type: 2021 vs 2025 vs 2032

1.3.2 Lipid Mediators

1.3.3 Peptides

1.3.4 Proteins

1.3.5 Small Molecule Synthetic Compounds

1.4 Market by Source

1.4.1 Global FPR2 Agonists and Antagonists Market Size Growth Rate by Source: 2021 vs 2025 vs 2032

1.4.2 Endogenous

1.4.3 Exogenous

1.5 Market by Application

1.5.1 Global FPR2 Agonists and Antagonists Market Growth by Application: 2021 vs 2025 vs 2032

1.5.2 Pharmaceutical Company

1.5.3 Universities and Research Institutes

1.5.4 Others

1.6 Assumptions and Limitations

1.7 Study Objectives

1.8 Years Considered

2 Global Growth Trends

2.1 Global FPR2 Agonists and Antagonists Market Perspective (2021–2032)

2.2 Global FPR2 Agonists and Antagonists Growth Trends by Region

2.2.1 Global FPR2 Agonists and Antagonists Market Size by Region: 2021 vs 2025 vs 2032

2.2.2 FPR2 Agonists and Antagonists Historic Market Size by Region (2021–2026)

2.2.3 FPR2 Agonists and Antagonists Forecasted Market Size by Region (2027–2032)

2.3 FPR2 Agonists and Antagonists Market Dynamics

2.3.1 FPR2 Agonists and Antagonists Industry Trends

2.3.2 FPR2 Agonists and Antagonists Market Drivers

2.3.3 FPR2 Agonists and Antagonists Market Challenges

2.3.4 FPR2 Agonists and Antagonists Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top FPR2 Agonists and Antagonists Players by Revenue

3.1.1 Global Top FPR2 Agonists and Antagonists Players by Revenue (2021–2026)

3.1.2 Global FPR2 Agonists and Antagonists Revenue Market Share by Players (2021–2026)

3.2 Global Top FPR2 Agonists and Antagonists Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

3.3 Global Key Players Ranking by FPR2 Agonists and Antagonists Revenue

3.4 Global FPR2 Agonists and Antagonists Market Concentration Ratio

3.4.1 Global FPR2 Agonists and Antagonists Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by FPR2 Agonists and Antagonists Revenue in 2025

3.5 Global Key Players of FPR2 Agonists and Antagonists Head Offices and Areas Served

3.6 Global Key Players of FPR2 Agonists and Antagonists, Products and Applications

3.7 Global Key Players of FPR2 Agonists and Antagonists, Date of General Availability (GA)

3.8 Mergers and Acquisitions, Expansion Plans

4 FPR2 Agonists and Antagonists Breakdown Data by Type

4.1 Global FPR2 Agonists and Antagonists Historic Market Size by Type (2021–2026)

4.2 Global FPR2 Agonists and Antagonists Forecasted Market Size by Type (2027–2032)

5 FPR2 Agonists and Antagonists Breakdown Data by Application

5.1 Global FPR2 Agonists and Antagonists Historic Market Size by Application (2021–2026)

5.2 Global FPR2 Agonists and Antagonists Forecasted Market Size by Application (2027–2032)

6 North America

6.1 North America FPR2 Agonists and Antagonists Market Size (2021–2032)

6.2 North America FPR2 Agonists and Antagonists Market Growth Rate by Country: 2021 vs 2025 vs 2032

6.3 North America FPR2 Agonists and Antagonists Market Size by Country (2021–2026)

6.4 North America FPR2 Agonists and Antagonists Market Size by Country (2027–2032)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe FPR2 Agonists and Antagonists Market Size (2021–2032)

7.2 Europe FPR2 Agonists and Antagonists Market Growth Rate by Country: 2021 vs 2025 vs 2032

7.3 Europe FPR2 Agonists and Antagonists Market Size by Country (2021–2026)

7.4 Europe FPR2 Agonists and Antagonists Market Size by Country (2027–2032)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific FPR2 Agonists and Antagonists Market Size (2021–2032)

8.2 Asia-Pacific FPR2 Agonists and Antagonists Market Growth Rate by Region: 2021 vs 2025 vs 2032

8.3 Asia-Pacific FPR2 Agonists and Antagonists Market Size by Region (2021–2026)

8.4 Asia-Pacific FPR2 Agonists and Antagonists Market Size by Region (2027–2032)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America FPR2 Agonists and Antagonists Market Size (2021–2032)

9.2 Latin America FPR2 Agonists and Antagonists Market Growth Rate by Country: 2021 vs 2025 vs 2032

9.3 Latin America FPR2 Agonists and Antagonists Market Size by Country (2021–2026)

9.4 Latin America FPR2 Agonists and Antagonists Market Size by Country (2027–2032)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa FPR2 Agonists and Antagonists Market Size (2021–2032)

10.2 Middle East & Africa FPR2 Agonists and Antagonists Market Growth Rate by Country: 2021 vs 2025 vs 2032

10.3 Middle East & Africa FPR2 Agonists and Antagonists Market Size by Country (2021–2026)

10.4 Middle East & Africa FPR2 Agonists and Antagonists Market Size by Country (2027–2032)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Bio-Techne

11.1.1 Bio-Techne Company Details

11.1.2 Bio-Techne Business Overview

11.1.3 Bio-Techne FPR2 Agonists and Antagonists Introduction

11.1.4 Bio-Techne Revenue in FPR2 Agonists and Antagonists Business (2021–2026)

11.1.5 Bio-Techne Recent Development

11.2 Abcam

11.2.1 Abcam Company Details

11.2.2 Abcam Business Overview

11.2.3 Abcam FPR2 Agonists and Antagonists Introduction

11.2.4 Abcam Revenue in FPR2 Agonists and Antagonists Business (2021–2026)

11.2.5 Abcam Recent Development

11.3 Enzo Life Sciences

11.3.1 Enzo Life Sciences Company Details

11.3.2 Enzo Life Sciences Business Overview

11.3.3 Enzo Life Sciences FPR2 Agonists and Antagonists Introduction

11.3.4 Enzo Life Sciences Revenue in FPR2 Agonists and Antagonists Business (2021–2026)

11.3.5 Enzo Life Sciences Recent Development

11.4 MedChemExpress

11.4.1 MedChemExpress Company Details

11.4.2 MedChemExpress Business Overview

11.4.3 MedChemExpress FPR2 Agonists and Antagonists Introduction

11.4.4 MedChemExpress Revenue in FPR2 Agonists and Antagonists Business (2021–2026)

11.4.5 MedChemExpress Recent Development

11.5 Anaspec

11.5.1 Anaspec Company Details

11.5.2 Anaspec Business Overview

11.5.3 Anaspec FPR2 Agonists and Antagonists Introduction

11.5.4 Anaspec Revenue in FPR2 Agonists and Antagonists Business (2021–2026)

11.5.5 Anaspec Recent Development

11.6 Merck

11.6.1 Merck Company Details

11.6.2 Merck Business Overview

11.6.3 Merck FPR2 Agonists and Antagonists Introduction

11.6.4 Merck Revenue in FPR2 Agonists and Antagonists Business (2021–2026)

11.6.5 Merck Recent Development

11.7 Discoverx

11.7.1 Discoverx Company Details

11.7.2 Discoverx Business Overview

11.7.3 Discoverx FPR2 Agonists and Antagonists Introduction

11.7.4 Discoverx Revenue in FPR2 Agonists and Antagonists Business (2021–2026)

11.7.5 Discoverx Recent Development

11.8 BioGems

11.8.1 BioGems Company Details

11.8.2 BioGems Business Overview

11.8.3 BioGems FPR2 Agonists and Antagonists Introduction

11.8.4 BioGems Revenue in FPR2 Agonists and Antagonists Business (2021–2026)

11.8.5 BioGems Recent Development

11.9 GenScript Company

11.9.1 GenScript Company Company Details

11.9.2 GenScript Company Business Overview

11.9.3 GenScript Company FPR2 Agonists and Antagonists Introduction

11.9.4 GenScript Company Revenue in FPR2 Agonists and Antagonists Business (2021–2026)

11.9.5 GenScript Company Recent Development

11.10 Alomone Labs

11.10.1 Alomone Labs Company Details

11.10.2 Alomone Labs Business Overview

11.10.3 Alomone Labs FPR2 Agonists and Antagonists Introduction

11.10.4 Alomone Labs Revenue in FPR2 Agonists and Antagonists Business (2021–2026)

11.10.5 Alomone Labs Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

List of Tables

Table 1. Global FPR2 Agonists and Antagonists Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032

Table 2. Key Players of Agonists

Table 3. Key Players of Antagonists

Table 4. Global FPR2 Agonists and Antagonists Market Size Growth Rate by Molecular Type (US$ Million): 2021 vs 2025 vs 2032

Table 5. Key Players of Lipid Mediators

Table 6. Key Players of Peptides

Table 7. Key Players of Proteins

Table 8. Key Players of Small Molecule Synthetic Compounds

Table 9. Global FPR2 Agonists and Antagonists Market Size Growth Rate by Source (US$ Million): 2021 vs 2025 vs 2032

Table 10. Key Players of Endogenous

Table 11. Key Players of Exogenous

Table 12. Global FPR2 Agonists and Antagonists Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032

Table 13. Global FPR2 Agonists and Antagonists Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 14. Global FPR2 Agonists and Antagonists Market Size by Region (US$ Million), 2021–2026

Table 15. Global FPR2 Agonists and Antagonists Market Share by Region (2021–2026)

Table 16. Global FPR2 Agonists and Antagonists Forecasted Market Size by Region (US$ Million), 2027–2032

Table 17. Global FPR2 Agonists and Antagonists Market Share by Region (2027–2032)

Table 18. FPR2 Agonists and Antagonists Market Trends

Table 19. FPR2 Agonists and Antagonists Market Drivers

Table 20. FPR2 Agonists and Antagonists Market Challenges

Table 21. FPR2 Agonists and Antagonists Market Restraints

Table 22. Global FPR2 Agonists and Antagonists Revenue by Players (US$ Million), 2021–2026

Table 23. Global FPR2 Agonists and Antagonists Market Share by Players (2021–2026)

Table 24. Global Top FPR2 Agonists and Antagonists Players by Tier (Tier 1, Tier 2, and Tier 3), based on FPR2 Agonists and Antagonists Revenue, 2025

Table 25. Ranking of Global Top FPR2 Agonists and Antagonists Companies by Revenue (US$ Million) in 2025

Table 26. Global 5 Largest Players Market Share by FPR2 Agonists and Antagonists Revenue (CR5 and HHI), 2021–2026

Table 27. Global Key Players of FPR2 Agonists and Antagonists, Headquarters and Area Served

Table 28. Global Key Players of FPR2 Agonists and Antagonists, Products and Applications

Table 29. Global Key Players of FPR2 Agonists and Antagonists, Date of General Availability (GA)

Table 30. Mergers and Acquisitions, Expansion Plans

Table 31. Global FPR2 Agonists and Antagonists Market Size by Type (US$ Million), 2021–2026

Table 32. Global FPR2 Agonists and Antagonists Revenue Market Share by Type (2021–2026)

Table 33. Global FPR2 Agonists and Antagonists Forecasted Market Size by Type (US$ Million), 2027–2032

Table 34. Global FPR2 Agonists and Antagonists Revenue Market Share by Type (2027–2032)

Table 35. Global FPR2 Agonists and Antagonists Market Size by Application (US$ Million), 2021–2026

Table 36. Global FPR2 Agonists and Antagonists Revenue Market Share by Application (2021–2026)

Table 37. Global FPR2 Agonists and Antagonists Forecasted Market Size by Application (US$ Million), 2027–2032

Table 38. Global FPR2 Agonists and Antagonists Revenue Market Share by Application (2027–2032)

Table 39. North America FPR2 Agonists and Antagonists Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 40. North America FPR2 Agonists and Antagonists Market Size by Country (US$ Million), 2021–2026

Table 41. North America FPR2 Agonists and Antagonists Market Size by Country (US$ Million), 2027–2032

Table 42. Europe FPR2 Agonists and Antagonists Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 43. Europe FPR2 Agonists and Antagonists Market Size by Country (US$ Million), 2021–2026

Table 44. Europe FPR2 Agonists and Antagonists Market Size by Country (US$ Million), 2027–2032

Table 45. Asia-Pacific FPR2 Agonists and Antagonists Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032

Table 46. Asia-Pacific FPR2 Agonists and Antagonists Market Size by Region (US$ Million), 2021–2026

Table 47. Asia-Pacific FPR2 Agonists and Antagonists Market Size by Region (US$ Million), 2027–2032

Table 48. Latin America FPR2 Agonists and Antagonists Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 49. Latin America FPR2 Agonists and Antagonists Market Size by Country (US$ Million), 2021–2026

Table 50. Latin America FPR2 Agonists and Antagonists Market Size by Country (US$ Million), 2027–2032

Table 51. Middle East & Africa FPR2 Agonists and Antagonists Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 52. Middle East & Africa FPR2 Agonists and Antagonists Market Size by Country (US$ Million), 2021–2026

Table 53. Middle East & Africa FPR2 Agonists and Antagonists Market Size by Country (US$ Million), 2027–2032

Table 54. Bio-Techne Company Details

Table 55. Bio-Techne Business Overview

Table 56. Bio-Techne FPR2 Agonists and Antagonists Product

Table 57. Bio-Techne Revenue in FPR2 Agonists and Antagonists Business (US$ Million), 2021–2026

Table 58. Bio-Techne Recent Development

Table 59. Abcam Company Details

Table 60. Abcam Business Overview

Table 61. Abcam FPR2 Agonists and Antagonists Product

Table 62. Abcam Revenue in FPR2 Agonists and Antagonists Business (US$ Million), 2021–2026

Table 63. Abcam Recent Development

Table 64. Enzo Life Sciences Company Details

Table 65. Enzo Life Sciences Business Overview

Table 66. Enzo Life Sciences FPR2 Agonists and Antagonists Product

Table 67. Enzo Life Sciences Revenue in FPR2 Agonists and Antagonists Business (US$ Million), 2021–2026

Table 68. Enzo Life Sciences Recent Development

Table 69. MedChemExpress Company Details

Table 70. MedChemExpress Business Overview

Table 71. MedChemExpress FPR2 Agonists and Antagonists Product

Table 72. MedChemExpress Revenue in FPR2 Agonists and Antagonists Business (US$ Million), 2021–2026

Table 73. MedChemExpress Recent Development

Table 74. Anaspec Company Details

Table 75. Anaspec Business Overview

Table 76. Anaspec FPR2 Agonists and Antagonists Product

Table 77. Anaspec Revenue in FPR2 Agonists and Antagonists Business (US$ Million), 2021–2026

Table 78. Anaspec Recent Development

Table 79. Merck Company Details

Table 80. Merck Business Overview

Table 81. Merck FPR2 Agonists and Antagonists Product

Table 82. Merck Revenue in FPR2 Agonists and Antagonists Business (US$ Million), 2021–2026

Table 83. Merck Recent Development

Table 84. Discoverx Company Details

Table 85. Discoverx Business Overview

Table 86. Discoverx FPR2 Agonists and Antagonists Product

Table 87. Discoverx Revenue in FPR2 Agonists and Antagonists Business (US$ Million), 2021–2026

Table 88. Discoverx Recent Development

Table 89. BioGems Company Details

Table 90. BioGems Business Overview

Table 91. BioGems FPR2 Agonists and Antagonists Product

Table 92. BioGems Revenue in FPR2 Agonists and Antagonists Business (US$ Million), 2021–2026

Table 93. BioGems Recent Development

Table 94. GenScript Company Company Details

Table 95. GenScript Company Business Overview

Table 96. GenScript Company FPR2 Agonists and Antagonists Product

Table 97. GenScript Company Revenue in FPR2 Agonists and Antagonists Business (US$ Million), 2021–2026

Table 98. GenScript Company Recent Development

Table 99. Alomone Labs Company Details

Table 100. Alomone Labs Business Overview

Table 101. Alomone Labs FPR2 Agonists and Antagonists Product

Table 102. Alomone Labs Revenue in FPR2 Agonists and Antagonists Business (US$ Million), 2021–2026

Table 103. Alomone Labs Recent Development

Table 104. Research Programs/Design for This Report

Table 105. Key Data Information from Secondary Sources

Table 106. Key Data Information from Primary Sources

Table 107. Authors List of This Report

List of Figures

Figure 1. FPR2 Agonists and Antagonists Picture

Figure 2. Global FPR2 Agonists and Antagonists Market Size Comparison by Type (US$ Million), 2021–2032

Figure 3. Global FPR2 Agonists and Antagonists Market Share by Type: 2025 vs 2032

Figure 4. Agonists Features

Figure 5. Antagonists Features

Figure 6. Global FPR2 Agonists and Antagonists Market Size Comparison by Molecular Type (US$ Million), 2021–2032

Figure 7. Lipid Mediators Features

Figure 8. Peptides Features

Figure 9. Proteins Features

Figure 10. Small Molecule Synthetic Compounds Features

Figure 11. Global FPR2 Agonists and Antagonists Market Size Comparison by Source (US$ Million), 2021–2032

Figure 12. Endogenous Features

Figure 13. Exogenous Features

Figure 14. Global FPR2 Agonists and Antagonists Market Size by Application (US$ Million), 2021–2032

Figure 15. Global FPR2 Agonists and Antagonists Market Share by Application: 2025 vs 2032

Figure 16. Pharmaceutical Company Case Studies

Figure 17. Universities and Research Institutes Case Studies

Figure 18. Others Case Studies

Figure 19. FPR2 Agonists and Antagonists Report Years Considered

Figure 20. Global FPR2 Agonists and Antagonists Market Size (US$ Million), Year-over-Year: 2021–2032

Figure 21. Global FPR2 Agonists and Antagonists Market Size, (US$ Million), 2021 vs 2025 vs 2032

Figure 22. Global FPR2 Agonists and Antagonists Market Share by Region: 2025 vs 2032

Figure 23. Global FPR2 Agonists and Antagonists Market Share by Players in 2025

Figure 24. Global FPR2 Agonists and Antagonists Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 25. The Top 10 and 5 Players Market Share by FPR2 Agonists and Antagonists Revenue in 2025

Figure 26. North America FPR2 Agonists and Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 27. North America FPR2 Agonists and Antagonists Market Share by Country (2021–2032)

Figure 28. United States FPR2 Agonists and Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 29. Canada FPR2 Agonists and Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 30. Europe FPR2 Agonists and Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 31. Europe FPR2 Agonists and Antagonists Market Share by Country (2021–2032)

Figure 32. Germany FPR2 Agonists and Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 33. France FPR2 Agonists and Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 34. U.K. FPR2 Agonists and Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 35. Italy FPR2 Agonists and Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 36. Russia FPR2 Agonists and Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 37. Ireland FPR2 Agonists and Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 38. Asia-Pacific FPR2 Agonists and Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 39. Asia-Pacific FPR2 Agonists and Antagonists Market Share by Region (2021–2032)

Figure 40. China FPR2 Agonists and Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 41. Japan FPR2 Agonists and Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 42. South Korea FPR2 Agonists and Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 43. Southeast Asia FPR2 Agonists and Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 44. India FPR2 Agonists and Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 45. Australia & New Zealand FPR2 Agonists and Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 46. Latin America FPR2 Agonists and Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 47. Latin America FPR2 Agonists and Antagonists Market Share by Country (2021–2032)

Figure 48. Mexico FPR2 Agonists and Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 49. Brazil FPR2 Agonists and Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 50. Middle East & Africa FPR2 Agonists and Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 51. Middle East & Africa FPR2 Agonists and Antagonists Market Share by Country (2021–2032)

Figure 52. Israel FPR2 Agonists and Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 53. Saudi Arabia FPR2 Agonists and Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 54. UAE FPR2 Agonists and Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 55. Bio-Techne Revenue Growth Rate in FPR2 Agonists and Antagonists Business (2021–2026)

Figure 56. Abcam Revenue Growth Rate in FPR2 Agonists and Antagonists Business (2021–2026)

Figure 57. Enzo Life Sciences Revenue Growth Rate in FPR2 Agonists and Antagonists Business (2021–2026)

Figure 58. MedChemExpress Revenue Growth Rate in FPR2 Agonists and Antagonists Business (2021–2026)

Figure 59. Anaspec Revenue Growth Rate in FPR2 Agonists and Antagonists Business (2021–2026)

Figure 60. Merck Revenue Growth Rate in FPR2 Agonists and Antagonists Business (2021–2026)

Figure 61. Discoverx Revenue Growth Rate in FPR2 Agonists and Antagonists Business (2021–2026)

Figure 62. BioGems Revenue Growth Rate in FPR2 Agonists and Antagonists Business (2021–2026)

Figure 63. GenScript Company Revenue Growth Rate in FPR2 Agonists and Antagonists Business (2021–2026)

Figure 64. Alomone Labs Revenue Growth Rate in FPR2 Agonists and Antagonists Business (2021–2026)

Figure 65. Bottom-up and Top-down Approaches for This Report

Figure 66. Data Triangulation

Figure 67. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions